Citi initiated coverage of Denali Therapeutics with a Buy rating and $32 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNLI:
- Denali Therapeutics reinstated with an Overweight at JPMorgan
- Denali Therapeutics participates in a conference call with B. Riley
- Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
- Denali Therapeutics reports Q3 EPS (72c), consensus (82c)
- Denali Therapeutics assumed with an Overweight at Cantor Fitzgerald